Your current position:HOME > Products & Services > Tumor Gene Detection > Gastric Cancer
Products & Services
Summary of Gastric Cancer
China is one of the countries with the highest incidence of gastric cancer, and the number of new cases of gastric cancer account for more than 40% of that of the world. According to the latest statistic data, there were 679,000 new cases of gastric cancer in 2015 and about 498,000 death cases, with death rate ranking second. Eating disorders, helicobacter pylori infection and genetic factors are important reasons for gastric cancer.

Scientific studies have verified that cancer is caused by the genetic mutation of human body, genetic mutation can lead to infinite proliferation of cells due to losing of normal control ability, eventually resulting in occurrence of cancer. While the targeted drugs can kill the tumor cells carrying specific gene variations, with apparent curative effects, therefore in several kinds of cancers, it is regarded as the first choice of treatment for advanced cancer patients. As for different patients, the genovariation they carry also has a tremendous difference, such differences cause the different sensitivity and toxicity reaction of each patient with the same targeted drug.

The precision diagnosis is a prerequisite for accurate medication. The idea of molecular genotype makes the doctors formulate best therapeutic regimen according to biomarkers carried by renal cancer patients and corresponding clinical status, to greatly find out potentially available targeted drugs and enhance treatment efficiency of antineoplastic drugs.

  The occurrence of tumors is often accompanied by multiple gene variations and heterogeneity. The second generation sequencing technology can realize parallel detection on multiple genes, saving samples compared to traditional detection methods and reaching higher technology sensitivity, to restore tumor mutation in a more real manner.
Gastric core™

Gene detection of individualized medication of gastric cancer

Buring Rock Gastric core™, targeted at patients with gastric cancer, by applying the advanced second generation sequencing technique, can comprehensively detect the drug-inhibited target spot related to gastric cancer, which clinically provides reference information of selection for individualized treatment for gastric cancer.

Genes covered in Gastric core™


Targeted drugs covered in Gastric core™


More comprehensive individualized medication choice:

Gastric core™ comprehensively detects drug-inhibited target gene suggested in gastric cancer NCCN guideline, drug-inhibited target spot researched in the phase Ⅱ/Ⅲ clinical trial of gastric cancer and approved drug-inhibited target spot of all kinds of cancers, provides the most comprehensive genetic detecting of individualized medication  of gastric cancer.

More accurate gene mutation detection related to gastric cancer:

The gene detection Panel based on the second generation sequencing technology optimized by Burning Rock Dx, can detect 4 types of variation types at one time (mutation, insertion and deletion, fusion, amplification, etc.), at the same time, applies deep sequencing to deeply cover trace genovariation, so as to provide full view of the precise genovariation although samples are limited. On the one hand, the parallel detecting with the polygenic high sensitivity  improves the detection rate of drug-inhibited genovariation, which is able to miss opportunity of dedication; On the other hand, the complete coverage of exons can detect the hot spots and rare even unknown genovariation at the same time in one detection, detect related drug-resistant mutation while discovering drug sensitivity mutation,  having an accurate reflection of the sensitivity and drug resistance information of the patients after the usage of medication.

More professional detection report interpretation:

Buring Rock Dx, having the patented automated analysis system, is also the domestic third party detecting company only owning the professional medical department. The improved software and hardware resources ensures the accuracy of every detection report, which provides accurate and comprehensive basis of designing more reasonable individualized treatment scheme for doctors.

Applicable Populations

Sample Requirements

Operation organization and biopsy samples, fresh tissues or paraffin embedding samples are available.

Service Cycle

After sample inspection, detailed detection report will be issued in 10 natural days.

Service Procedure

Cases Sharing